• Pancreatic ductal adenocarcinoma (PDAC) has the poorest prognosis among all malignancies and it is resistant to virtually all current therapies. (cell-signaling-pathways.com)
  • Therefore, we developed mKate2-expressing CFPAC-1 cell line, a well-established human pancreatic cell line, and deployed it in the subsequent SB 203580 kinase inhibitor xenograft model to test the efficacy of VNP20009 in the treatment of PDAC. (cell-signaling-pathways.com)
  • Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal human malignancies and a major health problem. (wikipedia.org)
  • Objective Pancreatic ductal adenocarcinoma (PDAC) is the most lethal malignancy and lacks effective treatment. (bmj.com)
  • Conclusions Our work provides novel mechanistic insights into understanding PDAC metastasis by the TAM-CAF interaction and targeting each of these signalling components would provide an attractive and new paradigm for treating pancreatic cancer. (bmj.com)
  • The splicing factor SF3B1 is recurrently mutated in various tumors, including pancreatic ductal adenocarcinoma (PDAC). (biorxiv.org)
  • Pancreatic ductal adenocarcinoma (PDAC) is the most prevalent neoplastic disease of the pancreas, with high metastatic potential, accounting for more than 90% of all pancreatic malignancies and is a highly devastating disease with poor prognosis and rising incidence. (biospace.com)
  • Advanced hepatocellular carcinoma, pancreatic ductal adenocarcinoma (PDAC) and biliary tract cancer. (medscape.com)
  • The incidence of pancreatic ductal adenocarcinoma (PDAC) is increasing and mortality is still high. (muni.cz)
  • It has already been shown that PDAC is not a single disease but a very heterogeneous malignancy. (muni.cz)
  • Pancreatic ductal adenocarcinoma (PDAC) accounts for about 95% of pancreatic cancer cases and is considered the most aggressive type of pancreatic cancer [ 2 ]. (oncotarget.com)
  • Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest human malignancies. (bvsalud.org)
  • PD184352 has undergone clinical evaluation in phase I and phase II trials involving individuals with superior malignancies and inhibition of ERK1/2 phosphorylation in tumor tissues and peripheral blood mononuclear cells was observed at increased drug doses indicating that reaching wanted pharmacodynamic results in vivo was possible. (cret-signal.com)
  • Pancreatic ductal adenocarcinoma (PDA) is one of the most lethal malignancies characterized by an intense tumor stroma with hypoperfused regions a significant inflammatory response and pronounced therapy resistance. (biomedigs.org)
  • Current treatment for pancreatic cancer does not directly target tumor hypoxia a major mediator of aggressive growth early metastasis and therapy resistance. (biomedigs.org)
  • Downregulation of NF-κB by triptolide inhibited migration self-renewal activity stem cell-related signaling tumor consider and development of set up pancreatic cancers cells. (biomedigs.org)
  • Materials and Strategies Tumor cell lines BxPc-3 MIA-PaCa2 and AsPC-1 pancreatic cancers Epidermal Growth Factor Receptor Peptide (985-996) cell lines had been extracted from the American Type Epidermal Growth Factor Receptor Peptide (985-996) Lifestyle Collection (Manassas VA) and authenticated through the entire culture by the normal morphology. (biomedigs.org)
  • To test the efficacy of VNP20009 in treating pancreatic tumor, we also developed a novel far-red fluorescent xenogenic pancreatic tumor model in animals. (cell-signaling-pathways.com)
  • Results Generation and characterization of fluorescent VNP20009 and pancreatic cell lines We developed a system that allows us to simultaneously image both the implanted tumor and the treatment drug. (cell-signaling-pathways.com)
  • Despite the advanced presentation at diagnosis and aggressive clinical course typically observed in patients with pancreatic cancer, quantitative analysis of the timing of genetic evolution suggests that at least a decade takes place between the initial mutation and development of the first malignant (nonmetastatic) pancreatic cancer cell and that approximately 5 additional years are required for the primary tumor to develop metastatic potential (https://www.ncbi.nlm.nih.gov/pubmed/20981102). (drug-injury.com)
  • In summary, our data highlight MCT4 /SLC16A3 as a key gene for distinct hallmarks of tumor malignancy in glioma cells. (hindawi.com)
  • Besides, upregulated MCT4 has been linked to altered tumor metabolism as well as to increased growth and survival in breast and pancreatic cancer [ 33 , 34 ]. (hindawi.com)
  • We investigated the impact on tumor malignancy in F98 glioma cells using in silico analysis, in vitro cell culture assays, and ex vivo vascular organotypic glioma impact model (VOGIM) [ 35 ] by implanting F98 cells into rat brain slices. (hindawi.com)
  • Advanced pheochromocytoma/paraganglioma (PPGL) or pancreatic neuroendocrine tumor (pNET). (medscape.com)
  • Demonstrating that Hedgehog signaling may play a dual role in pancreatic cancer, acting as an oncogene in the early stages of disease and acting as a tumor-suppressor in the late stages of disease. (mayo.edu)
  • They were recently updated to recommend germline testing for any patient with pancreatic cancer and molecular analysis of any metastatic pancreatic tumor. (jnccn.org)
  • We observed similar metabolic alterations that correlated with MUC16 expression in primary tumor tissue specimens from human pancreatic adenocarcinoma cancer patients. (oncotarget.com)
  • Recommendations for screening of patients with CP for pancreatic cancer do not exist and, due to a wide diversity of clinical and morphological presentations of CP, the differentiation between CP and pancreatic cancer, especially in cases when malignant tumor growth appears in the course of CP, is challenging ( 4 ). (iiarjournals.org)
  • This study elucidates the effects of the intravenous (IV) lidocaine infusion on the biology of pancreatic circulating tumor cells (CTCs) isolated from patients undergoing robotic pancreatectomy for all types of pancreatic cancer. (policylab.us)
  • CT may demonstrate the tumor if the malignancy is nodular and masslike, but tumors of the diffuse sclerosing variety are difficult to detect. (medscape.com)
  • In contrast to pancreatic or colorectal malignancies, virally induced cancers e. g. (cret-signal.com)
  • Triptolide may be superior to current chemotherapeutics for treatment of pancreatic cancers therefore. (biomedigs.org)
  • Lewis commented: "Few GI malignancies have seen their therapeutic paradigm shift more in recent years than biliary tract cancers, but immunotherapy and MEK inhibition have yet to yield the same dividends in BTC as they have in melanoma. (medscape.com)
  • Most of the pancreatic cancers develop through a pancreatic intraepithelial neoplasm mechanism, which is basically dysplasia that increases over time until you have a full-blown pancreatic ductal adenocarcinoma," Dr. Tempero stated. (jnccn.org)
  • Hereditary breast and ovarian cancer syndrome has also been associated with an increased risk of other cancers such as prostate cancer, pancreatic ductal adenocarcinoma, and melanoma ( 3 ). (frontiersin.org)
  • As such, in the current review, we summarize the generation and biological functions of circRNAs and exosomes, analyze the mechanism of exosomal circRNAs in a wide variety of malignant tumors including solid cancers and hematological malignancies, and highlight their promising potential not only as diagnostic molecular markers but also as therapeutic targets. (biomedcentral.com)
  • Nearly 90% of pancreatic cancers are caused by oncogenic KRAS mutations. (bvsalud.org)
  • SAN DIEGO, May 25, 2023 (GLOBE NEWSWIRE) - Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced preliminary Phase 1b data for ERAS-007 combinations in patients with GI malignancies from two poster presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. (tarsadia.com)
  • Most pancreatic cancers are exocrine tumors that develop from ductal and acinar cells. (msdmanuals.com)
  • 10% of pancreatic cancers are associated with an underlying genetic component. (msdmanuals.com)
  • pancreatic cancer stem cells (CSCs) and evaluated the therapeutic effect of triptolide. (biomedigs.org)
  • PANACREAS stands for "Integrating chemical approaches to treat pancreatic cancer: making new leads for a cure" and is being supported through Coordination Theme 1 (Health) of the European Community's FP7. (wikipedia.org)
  • Both the incidence and the death rates for pancreatic cancer are increasing. (medscape.com)
  • The initial manifestations of pancreatic cancer are often nonspecific, and consequently are often misinterpreted. (medscape.com)
  • Pancreatic cancer is notoriously difficult to diagnose in its early stages. (medscape.com)
  • Laboratory findings in patients with pancreatic cancer are usually nonspecific. (medscape.com)
  • Occasionally, the presence of pancreatic cancer is suggested by elevated liver transaminase, bilirubin, and alkaline phosphatase levels on testing performed for other purposes. (medscape.com)
  • Patients with advanced pancreatic cancer and weight loss have laboratory evidence of malnutrition (eg, low serum albumin or cholesterol level). (medscape.com)
  • Surgery is the only potentially curative treatment modality for early-stage pancreatic cancer. (medscape.com)
  • Aims-To investigate the correlation between the expression of the p53 and mdm-2 oncoproteins and to assess their prognostic value in colorectal cancer.Methods-Using a polyclonal (CM1) and a monoclonal antibody directed against p53 and mdm-2, respectively, these oncoproteins were stained immunohistochemically in 109 colorectal adenocarcinomas.Result. (researchgate.net)
  • Pancreatic cancer as a general term usually refers to pancreatic adenocarcinoma, an aggressive malignant cancer with a poor prognosis. (rarediseases.org)
  • This suggests that a direct causal role for liraglutide in the initial development of pancreatic cancer in patients participating in the LEADER trial is unlikely given the short latency period between exposure and diagnosis of pancreatic cancer. (drug-injury.com)
  • There is insufficient information available to elucidate whether treatment plays a role in accelerating the evolution of primary or metastatic disease following occurrence of the initial mutation that will ultimately lead to clinically evident pancreatic cancer, given the relative short follow-up period (median follow-up of 3.5 years). (drug-injury.com)
  • In summary, taking into consideration the totality of information available, the additional information provided in LEADER does not appear to substantively alter the original FDA and EMA conclusions regarding the lack of sufficient information to conclusively determine whether long term exposure to GLP-RAs increase the risk of pancreatic cancer. (drug-injury.com)
  • Victoza, Januvia, Byetta] and the development of pancreatic cancer. (drug-injury.com)
  • We will continue to follow this pancreatic cancer safety issue for Victoza, Januvia, and Byetta, watching for any actions taken by the FDA and other drug regulators as well as monitoring the relevant medical journals. (drug-injury.com)
  • While recent cancer breakthrough therapies, most notably anti-PD-1 antibodies, have led to dramatic improvements in outcomes in many cancer settings, this is not the case for pancreatic cancer, which remains a devastating diagnosis for patients. (biospace.com)
  • Pancreatic cancer is the fourth leading cause of cancer-related deaths in Europe and the United States 1 and the seventh leading cause of cancer-related deaths worldwide 2 . (biospace.com)
  • Few treatment options exist for metastatic pancreatic cancer, and response rates to the standard of care therapy of gemcitabine/nab-paclitaxel remain very low. (biospace.com)
  • Despite the considerable expansion of knowledge in the development of pancreatic cancer, there has been little progress made in facilitating an early diagnosis of this disease and predicting an accurate response to treatment. (manchester.ac.uk)
  • In the second study, we explore the feasibility of gene expression profiling from RNA isolated from matched pancreatic juice and tumour tissue in patients with pancreatic cancer and pancreatic cystic tumours. (manchester.ac.uk)
  • RT-PCR was used to measure expression levels of 18 genes common to both pancreas cancer and pancreatic cystic tumours. (manchester.ac.uk)
  • In recent years, however, theranostics has been successfully applied to a whole range of other malignancies, including neuroendocrine tumors (NETs) and prostate cancer in particular. (snmjournals.org)
  • Although we are "winning the war against cancer," pancreatic malignancies are expected to be the most common cause of cancer-related death by 2040. (jnccn.org)
  • and Professor of Medicine, as well as Chair of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pancreatic Adenocarcinoma, noted that the rate of pancreatic cancer-related morality is increasing. (jnccn.org)
  • If this trend continues, pancreatic cancer is expected to be the most common cause of cancer-related death by 2040. (jnccn.org)
  • We don't really know why [pancreatic cancer] is so aggressive," Dr. Tempero commented. (jnccn.org)
  • On the other hand, the biologic development of pancreatic cancer is well understood. (jnccn.org)
  • In the phase II/III PRODIGE 4/ACCORD 11 trial, patients with metastatic pancreatic cancer were randomly assigned to receive gemcitabine or a combination chemotherapy regimen consisting of oxaliplatin/irinotecan/fluorouracil/leucovorin (FOLFIRINOX). (jnccn.org)
  • BRCA-associated hereditary breast and ovarian cancer syndrome (HBOC) is characterized by an increased risk of developing other malignancies including cholangiocarcinoma (CCA). (frontiersin.org)
  • P isters and colleagues from the M. D. Anderson Cancer Center offer a state-of-the-art discussion of the staging and treatment of pancreatic cancer. (cancernetwork.com)
  • Their treatise addresses most of the current issues of controversy surrounding this disease from a largely nonparochial standpoint, and should serve as a primer for the multidisciplinary approach to the treatment of pancreatic ductal cancer. (cancernetwork.com)
  • Most pancreatic surgeons believe that more (surgery) is not necessarily better for pancreatic cancer. (cancernetwork.com)
  • The M. D. Anderson group,[12] and for an even longer time the group from the Fox-Chase Cancer Center,[ 13] have been the pioneers of upfront (neoadjuvant) therapy for potentially resectable pancreatic cancer and continue to be outspoken advocates of this concept. (cancernetwork.com)
  • 2. Other malignancies within the past 3 years except for the following: adequately treated cervical or vulvar carcinoma in situ, treated basal cell or squamous carcinoma of the skin, superficial bladder tumors (Ta, Tis \& T1), ductal carcinoma in situ (DCIS) of the breast and low grade prostate cancer. (iu.edu)
  • In the current studies, we observed that MUC16 knockdown pancreatic cancer cells exhibit reduced glucose uptake and lactate secretion along with reduced migration and invasion potential, which can be restored by supplementing the culture media with lactate, an end product of aerobic glycolysis. (oncotarget.com)
  • Ectopic expression of c-MYC in MUC16 knockdown pancreatic cancer cells restores the altered cellular physiology. (oncotarget.com)
  • Our LC-MS/MS based metabolomics studies indicate global metabolic alterations in MUC16 knockdown pancreatic cancer cells, as compared to the controls. (oncotarget.com)
  • Overall, our results demonstrate that MUC16 plays an important role in metabolic reprogramming of pancreatic cancer cells by increasing glycolysis and enhancing motility and invasiveness. (oncotarget.com)
  • Pancreatic cancer is one of the deadliest malignancies and is the fourth leading cause of cancer-related deaths in the United States [ 1 ]. (oncotarget.com)
  • Despite substantial progress in the understanding and therapy of pancreatic cancer, the overall 5-year survival rate remains about 5% [ 3 ]. (oncotarget.com)
  • The lethal nature of pancreatic cancer is mainly correlated with its late diagnosis, high metastatic capacity to nearby organs, and resistance to therapeutic agents [ 4 ]. (oncotarget.com)
  • In addition, CP is considered a risk factor for pancreatic cancer, whereas the overall incidence of cancer occurrence remains unspecified ( 7 , 8 ). (iiarjournals.org)
  • A listing of 154 Pancreatic Cancer clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas. (policylab.us)
  • Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer. (uclahealth.org)
  • A mutated anti-CA19-9 scFv-Fc for positron emission tomography of human pancreatic cancer xenografts. (uclahealth.org)
  • Pancreatic cancer is one of the most aggressive of gastrointestinal malignancies, with a 5- year survival rate of 4-5% [ 1 , 2 ]. (biomedcentral.com)
  • Despite advances in surgical technique and reduction in postoperative mortality, the death rate for pancreatic cancer has remained relatively stable [ 4 ]. (biomedcentral.com)
  • Gene expression profiling of pancreatic cancer cells identifies more than 200 genes commonly regulated by STAT3 and oncogenic KRAS. (bvsalud.org)
  • Acinar cell carcinoma is a rare cause of pancreatic cancer. (msdmanuals.com)
  • Genetic testing is now offered routinely to all patients diagnosed with pancreatic cancer. (msdmanuals.com)
  • Symptoms of pancreatic cancer such as pain and weight loss are nonspecific, leading to a later diagnosis by which time the disease has spread. (msdmanuals.com)
  • Pancreatic cancer causes diabetes in up to half of patients, leading to symptoms of glucose intolerance (eg, polyuria and polydipsia). (msdmanuals.com)
  • Pancreatic cancer survival by stage and age in seven high-income countries (ICBP SURVMARK-2): a population-based study. (who.int)
  • Pancreatic cancer: an increasing global public health concern. (who.int)
  • This prospective cohort study aims to investigate the incidence, related factors and prognosis of IgG4-related disease (IgG4-RD) with malignancies in the Chinese cohort. (nature.com)
  • Data regarding demographics, clinical features, treatment and prognosis of IgG4-RD patients complicating malignancies were collected and compared to those of age- and sex-matched controls. (nature.com)
  • It is also important to know the risk factors and prognosis for IgG4-RD patients harboring malignancies. (nature.com)
  • Approximately 95 percent of pancreatic malignancies are adenocarcinomas, for which the prognoses are in general worse than the prognosis of G1- and G2 pNENs. (rarediseases.org)
  • G3 neuroendocrine carcinomas have a similar poor prognosis as pancreatic adenocarinomas. (rarediseases.org)
  • Possible complications include dilatation, distortion and stricture of the pancreatic ducts, calcification of the pancreatic parenchyma, formation of pseudocysts, duodenal or common bile duct stenosis, or the formation of superior mesenteric, portal or splenic vein thrombosis which may each severely affect the patient's quality of life and overall prognosis ( 1 , 6 ). (iiarjournals.org)
  • It has a better prognosis than traditional ductal adenocarcinoma. (msdmanuals.com)
  • Thus, it falls into the differential diagnosis of other peritoneal malignancies including malignant mesothelioma. (nih.gov)
  • Pancreatic ductal adenocarcinomas, especially when poorly differentiated/undifferentiated, may be diffusely and strongly positive for calretinin creating a potential diagnostic challenge with malignant mesothelioma. (nih.gov)
  • The most common cause of malignant biliary obstruction is pancreatic adenocarcinoma . (medscape.com)
  • Gross section of an adenocarcinoma of the pancreas measuring 5 × 6 cm resected from the pancreatic body and tail. (medscape.com)
  • Pancreatic neuroendocrine neoplasms (pNENs) are an increasingly common group of malignancies that arise within the endocrine tissue of the pancreas. (rarediseases.org)
  • Chronic pancreatitis (CP) is a progressively evolving inflammation of the pancreas along with destruction of the pancreatic parenchyma and its replacement by fibrotic tissue that results in progressive loss of endocrine and exocrine functionality ( 1 ). (iiarjournals.org)
  • Adenocarcinomas of the head of the pancreas cause obstructive jaundice (which can cause pruritus) in 80 to 90% of patients. (msdmanuals.com)
  • Tumors expressing calretinin without other mesothelial markers should prompt a careful evaluation of the morphologic and immunohistochemical features to exclude other malignancies. (nih.gov)
  • There is also an adenoma/adenocarcinoma sequence where benign tumors, such as intraductal papillary mucinous neoplasm and mucinous cystic neoplasm…, can transform into what looks exactly like the disease process of the other pathway. (jnccn.org)
  • It has been suggested that MUC17 expression is correlated with the malignancy potential of pancreatic ductal adenocarcinomas (PDACs). (nih.gov)
  • Ten of them developed malignancy after the diagnosis of IgG4-RD, given a standard incidence ratio (SIR) of 2.78 (95%CI 1.33-5.12). (nature.com)
  • Moreover, it is difficult for clinicians to make a diagnosis of IgG4-RD because it can manifest as mass lesions, leading to an occasional misdiagnosis of malignancy. (nature.com)
  • If the diagnosis of pancreatic ductal adenocarcinoma is considered, ductal differentiation can be demonstrated by using additional immunohistochemical markers such as mucin-related glycoproteins (MUC1, MUC5AC) and/or oncoproteins (CEA, B72.3, CA125). (nih.gov)
  • We conclude that an increased incidence of malignancy was found in Chinese IgG4-RD cohort. (nature.com)
  • We sought to describe the incidence and clinical characteristics of malignancies in patients with IgG4-RD. Based on these results, significant factors were evaluated to determine whether they were related to malignancy. (nature.com)
  • In this study, we explored the incidence of calretinin expression in pancreatic ductal adenocarcinoma. (nih.gov)
  • The high incidence of incidental pancreatic adenocarcinoma especially underlines the necessity for an early surgical therapeutic approach for these patients. (iiarjournals.org)
  • Their mass-like clinicopathological presentations and radiologically 18 F-FDG-avid hypermetabolic lesions has made it to be one of the great malignancy mimickers 2 . (nature.com)
  • This is an open-label, prospective phase two basket trial assessing the efficacy of ulixertinib in combination with hydroxychloroquine in patients with advanced gastrointestinal malignancies. (ucbraid.org)
  • This is an open-label, multicenter, phase II basket study of ulixertinib in combination with hydroxychloroquine in patients with advanced gastrointestinal malignancies harboring rat sarcoma virus (RAS), a member of the rapidly accelerated fibrosarcoma (non-V600 BRAF), extracellular signal-regulated kinase (ERK), or mitogen-activated protein kinase (MEK) mutations. (ucbraid.org)
  • The symptoms, severity and rate of progression of pNENs can vary greatly from one person to another, even among individuals with the same type of malignancy. (rarediseases.org)
  • MUC16, a transmembrane mucin, facilitates pancreatic adenocarcinoma progression and metastasis. (oncotarget.com)
  • Combination Therapy with a Bispecific Antibody Targeting the hERG1/β1 Integrin Complex and Gemcitabine in Pancreatic Ductal Adenocarcinoma. (unifi.it)
  • Patients with pancreatic adenocarcinoma must have progressed during or after first-line therapy of FOLFIRINOX/ mFOLFIRINOX, gemcitabine/nab-paclitaxel unless deemed ineligible by the treating investigator to receive chemotherapy-based regimens due to prior comorbidities. (ucbraid.org)
  • Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. (cancercentrum.se)
  • We report the case of a 74-year-old woman who presented with late-onset (recurrent disease), solitary, subcutaneous metastasis in the posterior aspect of the left thigh, deriving from a pancreatic head adenocarcinoma, 2 years after initial treatment with R0 resection (pancreaticoduodenectomy) and adjuvant chemotherapy. (amjcaserep.com)
  • Cholangiocarcinoma is a slow-growing malignancy of the bile duct. (medscape.com)
  • A study of nearly one million people who underwent a CT scan before 22 years of age finds that the radiation from CT scans increased the risk of hematological malignancies in a dose-dependent manner. (nature.com)
  • Additionally, emerging studies in the last 1 ~ 2 years have revealed that exosomal circRNA also have effect on hematological malignancies. (biomedcentral.com)
  • 1 , 2 To address the unmet needs and clinical challenges faced by this patient population, Dr. Tempero presented an update on systemic therapy options and relevant changes to the NCCN Guidelines for Pancreatic Adenocarcinoma at the NCCN 2022 Annual Conference. (jnccn.org)
  • BRCA mutations were detected in 3.6% of biliary tract malignancies examined in a recent study ( 4 ). (frontiersin.org)
  • Surgical resection offers the only potential for cure, but no more than 20% of pancreatic carcinomas are resectable [ 2 ]. (biomedcentral.com)
  • They often are the first clinical manifestation of a previously unknown malignancy of an advanced stage, but may also be solitary in a setting of a recurrent disease. (amjcaserep.com)
  • Early clinical data from HERKULES-3 continue to reinforce the potential to combine ERAS-007 with multiple agents and its potential as a backbone therapy to treat patients with GI malignancies. (tarsadia.com)
  • Clinical evaluation, imaging studies, indications for cytologic study and preprocedural requirements for duct brushing studies and pancreatic fine-needle aspiration: The Papanicolaou Society of Cytopathology Guidelines. (cancercentrum.se)
  • Patients who underwent surgery with curative intent for pancreatic ductal adenocarcinoma between 8/3/96 and 21/6/11 were included in this study. (biomedcentral.com)
  • We prospectively analyzed the IgG4-RD patients recruited in Peking Union Medical College Hospital from January 2011 to August 2018 and identified patients diagnosed with IgG4-RD complicating malignancies. (nature.com)
  • Pancreatic ductal adenocarcinoma is one of the most common causes of "peritoneal carcinomatosis" and has an insidious growth pattern. (nih.gov)
  • Our researchers are now developing a similar noninvasive method for early detection of hepatobiliary malignancies. (mayo.edu)
  • See also Pancreatic Adenocarcinoma Imaging: What You Need to Know , a Critical Images slideshow, to help identify which imaging studies to use to identify and evaluate this disease. (medscape.com)